LaNova Medicines
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Jinxiang Road Building a 861 Fl 8, Pudon...Phone Number
+86 2168889618Website
www.lanovamedicines.comRevenue
$48.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About LaNova Medicines
Founded in September 2019, LaNova Medicines Ltd. is a privately held biotech company headquartered in Shanghai. With the mission of "Care for life, Dedicate to innovation", the Company focuses on discovering novel biologic therapies in the fields of ADC and Immuno-Oncology, with a commitment to developing best-in-class or first-in-class therapies that address significant unmet medical needs.Explore more
LaNova Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LaNova Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on LaNova Medicines recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at LaNova Medicines
Website visits: Recent activity has been detected on your website
Check if LaNova Medicines has recently received funding, and reach out quickly before it becomes old news!
LaNova Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once LaNova Medicines has new funding data
Product Launch: Get notified when LaNova Medicines launches new products
Click to see if LaNova Medicines had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if LaNova Medicines is spiking on competitors!
Recommended Actions
Find VP level buyers at LaNova Medicines
Find 2 more new buyers
Company Profile Activity
Activity Insights
LaNova Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
LaNova Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about LaNova Medicines.
LaNova Medicines financials insights
Gather financial insights about LaNova Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series C
$42M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Partnership
Partnership, Research & Development, Product Management, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals, Sales Operations
LaNova Medicines News & Media
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy. From the left, Rhee Byung-geon, Chairman and CEO of GI Innovation, Dr. Crystal Quin, CEO of LaNova Medicines, and Jang Myoung-ho, CSO of GI Innovation. (Source: GI Innovation) This MOU was held on January 15th, local time, during JP Morgan HealthcareMerck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms anLaNova Medicines Announces Initiation of Phase 1 Clinical Trial of Anti-PD-1/VEGF Bispecific Antibody LM-299 and Completion of $42 Million Series C1 Financing
Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition of tumor growth and well-tolerated safety profile IND for LM-299 in the US expected to be submitted in the second half of...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding LaNova Medicines
Sign Up For FreeTo access detailed company insights
Founded in September 2019, LaNova Medicines Ltd. is a privately held biotech company headquartered in Shanghai. With the mission of "Care for life, Dedicate to innovation", the Company focuses on discovering novel biologic therapies in the fields of ADC and Immuno-Oncology, with a commitment to developing best-in-class or first-in-class therapies t... Read More
